Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.48 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913900 | 0.82 | HDAC6 (0.48) | HDAC6PPARGHDAC1HDAC4HDAC7 | |
| SCHEMBL4911372 | 0.79 | HDAC1 (0.36) | HDAC6PPARGHDAC1HDAC4HDAC7 | |
| SCHEMBL1684141 | 0.76 | HDAC6 (0.53) | HDAC6PPARGHDAC1HDAC4HDAC7 | |
| SCHEMBL2945762 | 0.76 | PPARG (0.51) | HDAC6PPARGHDAC1HDAC4HDAC7 | |
| SCHEMBL4914468 | 0.75 | PPARG (0.40) | HDAC6PPARGHDAC1HDAC8FSCN1 | |
| SCHEMBL4903870 | 0.72 | CYP2C19 (0.44) | HDAC6PPARG | |
| SCHEMBL5832076 | 0.71 | MMP13 (0.45) | HDAC6HDAC1HDAC4HDAC7HDAC11 | |
| SCHEMBL4903920 | 0.70 | HSP90AA1 (0.47) | — | |
| SCHEMBL2950141 | 0.69 | PPARG (0.45) | HDAC6PPARGHDAC1HDAC4HDAC7 | |
| SCHEMBL4909246 | 0.68 | EGLN1 (0.44) | HDAC6HDAC1HDAC4HDAC7HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | HDAC6 570/4885PPARG 2781/4885HDAC1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.